Carl L Gordon - Net Worth and Insider Trading
Carl L Gordon Net Worth
The estimated net worth of Carl L Gordon is at least $893 Million dollars as of 2024-04-24. Carl L Gordon is the Director, 10% Owner of Prevail Therapeutics Inc and owns about 13,822,463 shares of Prevail Therapeutics Inc (PRVL) stock worth over $318 Million. Carl L Gordon is the Director of Turning Point Therapeutics Inc and owns about 2,027,550 shares of Turning Point Therapeutics Inc (TPTX) stock worth over $154 Million. Carl L Gordon is also the Director, 10% Owner of Theseus Pharmaceuticals Inc and owns about 17,713,600 shares of Theseus Pharmaceuticals Inc (THRX) stock worth over $72 Million. Besides these, Carl L Gordon also holds Keros Therapeutics Inc (KROS) , Alector Inc (ALEC) , Intellia Therapeutics Inc (NTLA) , Terns Pharmaceuticals Inc (TERN) , Compass Therapeutics Inc (CMPX) , Adicet Bio Inc (ACET) , ArriVent BioPharma Inc (AVBP) , ORIC Pharmaceuticals Inc (ORIC) , ACADIA Pharmaceuticals Inc (ACAD) , BioCryst Pharmaceuticals Inc (BCRX) , X4 Pharmaceuticals Inc (XFOR) , Cartesian Therapeutics Inc (RNAC) , Kinnate Biopharma Inc (KNTE) , Pacira BioSciences Inc (PCRX) . Details can be seen in Carl L Gordon's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Carl L Gordon has not made any transactions after 2024-01-30 and currently still holds the listed stock(s).
Transaction Summary of Carl L Gordon
Carl L Gordon Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Carl L Gordon owns 22 companies in total, including Prevail Therapeutics Inc () , Turning Point Therapeutics Inc () , and ORIC Pharmaceuticals Inc () among others .
Click here to see the complete history of Carl L Gordon’s form 4 insider trades.
Insider Ownership Summary of Carl L Gordon
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
Prevail Therapeutics Inc | 2020-06-17 | director & 10 percent owner | |
Turning Point Therapeutics Inc | 2019-04-22 | director | |
ORIC Pharmaceuticals Inc | 2021-03-30 | director | |
Keros Therapeutics Inc | 2020-04-13 | director | |
SpringWorks Therapeutics Inc | 2019-09-12 | director & 10 percent owner | |
Alector Inc | 2019-02-11 | director & 10 percent owner | |
ARMO BioSciences Inc | 2018-06-22 | director | |
X4 Pharmaceuticals Inc | 2017-11-20 | director & 10 percent owner | |
Intellia Therapeutics Inc | 2016-05-11 | director & 10 percent owner | |
Cartesian Therapeutics Inc | 2016-06-27 | director & 10 percent owner | |
Acceleron Pharma Inc | 2013-09-18 | director | |
Amarin Corp PLC | 2011-02-28 | director | |
Pacira BioSciences Inc | 2011-02-08 | director | |
BioCryst Pharmaceuticals Inc | 2005-12-02 | director | |
ACADIA Pharmaceuticals Inc | 2005-04-20 | director | |
Adicet Bio Inc | 2024-01-25 | director | |
Compass Therapeutics Inc | 2022-11-08 | director & 10 percent owner | |
Theseus Pharmaceuticals Inc | 2023-07-17 | director & 10 percent owner | |
Kinnate Biopharma Inc | 2023-05-05 | director | |
Disc Medicine Inc | 2021-10-04 | director & 10 percent owner | |
Terns Pharmaceuticals Inc | 2022-12-23 | director & 10 percent owner | |
BiomX Inc | 2023-02-27 | 10 percent owner |
Carl L Gordon Latest Holdings Summary
Carl L Gordon currently owns a total of 17 stocks. Among these stocks, Carl L Gordon owns 13,822,463 shares of Prevail Therapeutics Inc (PRVL) as of June 24, 2019, with a value of $318 Million and a weighting of 35.61%. Carl L Gordon owns 2,027,550 shares of Turning Point Therapeutics Inc (TPTX) as of April 22, 2019, with a value of $154 Million and a weighting of 17.26%. Carl L Gordon also owns 17,713,600 shares of Theseus Pharmaceuticals Inc (THRX) as of July 17, 2023, with a value of $72 Million and a weighting of 8.06%. The other 14 stocks Keros Therapeutics Inc (KROS) , Alector Inc (ALEC) , Intellia Therapeutics Inc (NTLA) , Terns Pharmaceuticals Inc (TERN) , Compass Therapeutics Inc (CMPX) , Adicet Bio Inc (ACET) , ArriVent BioPharma Inc (AVBP) , ORIC Pharmaceuticals Inc (ORIC) , ACADIA Pharmaceuticals Inc (ACAD) , BioCryst Pharmaceuticals Inc (BCRX) , X4 Pharmaceuticals Inc (XFOR) , Cartesian Therapeutics Inc (RNAC) , Kinnate Biopharma Inc (KNTE) , Pacira BioSciences Inc (PCRX) have a combined weighting of 39.07% among all his current holdings.
Latest Holdings of Carl L Gordon
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
PRVL | Prevail Therapeutics Inc | 2019-06-24 | 13,822,463 | 23.00 | 317,916,649 |
TPTX | Turning Point Therapeutics Inc | 2019-04-22 | 2,027,550 | 76.01 | 154,114,076 |
THRX | Theseus Pharmaceuticals Inc | 2023-07-17 | 17,713,600 | 4.06 | 71,917,216 |
KROS | Keros Therapeutics Inc | 2020-04-13 | 1,268,734 | 55.19 | 70,021,429 |
ALEC | Alector Inc | 2019-02-11 | 13,094,029 | 5.34 | 69,922,115 |
NTLA | Intellia Therapeutics Inc | 2016-05-11 | 2,662,180 | 21.53 | 57,316,735 |
TERN | Terns Pharmaceuticals Inc | 2022-12-23 | 7,619,135 | 4.69 | 35,733,743 |
CMPX | Compass Therapeutics Inc | 2022-11-08 | 18,791,422 | 1.52 | 28,562,961 |
ACET | Adicet Bio Inc | 2024-01-25 | 11,447,140 | 2.10 | 24,038,994 |
AVBP | ArriVent BioPharma Inc | 2024-01-30 | 1,513,664 | 15.77 | 23,870,481 |
ORIC | ORIC Pharmaceuticals Inc | 2021-03-30 | 2,212,571 | 8.77 | 19,404,248 |
ACAD | ACADIA Pharmaceuticals Inc | 2005-04-20 | 621,606 | 16.73 | 10,399,468 |
BCRX | BioCryst Pharmaceuticals Inc | 2005-12-02 | 1,100,000 | 4.38 | 4,818,000 |
XFOR | X4 Pharmaceuticals Inc | 2017-11-20 | 1,868,966 | 1.23 | 2,298,828 |
RNAC | Cartesian Therapeutics Inc | 2016-06-27 | 60,847 | 20.59 | 1,252,840 |
KNTE | Kinnate Biopharma Inc | 2023-05-05 | 450,000 | 2.65 | 1,192,500 |
PCRX | Pacira BioSciences Inc | 2011-02-08 | 0 | 26.81 | 0 |
Holding Weightings of Carl L Gordon
Carl L Gordon Form 4 Trading Tracker
According to the SEC Form 4 filings, Carl L Gordon has made a total of 1 transactions in Prevail Therapeutics Inc (PRVL) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Prevail Therapeutics Inc is the acquisition of 882,352 shares on June 24, 2019, which cost Carl L Gordon around $15 Million.
According to the SEC Form 4 filings, Carl L Gordon has made a total of 0 transactions in Turning Point Therapeutics Inc (TPTX) over the past 5 years. The most-recent trade in Turning Point Therapeutics Inc is the acquisition of 360,000 shares on April 22, 2019, which cost Carl L Gordon around $6 Million.
According to the SEC Form 4 filings, Carl L Gordon has made a total of 5 transactions in Theseus Pharmaceuticals Inc (THRX) over the past 5 years, including 5 buys and 0 sells. The most-recent trade in Theseus Pharmaceuticals Inc is the acquisition of 479,932 shares on July 17, 2023, which cost Carl L Gordon around $1 Million.
More details on Carl L Gordon's insider transactions can be found in the Insider Trading History of Carl L Gordon table.Insider Trading History of Carl L Gordon
- 1
Carl L Gordon Trading Performance
GuruFocus tracks the stock performance after each of Carl L Gordon's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Carl L Gordon is 9.77%. GuruFocus also compares Carl L Gordon's trading performance to market benchmark return within the same time period. The performance of stocks bought by Carl L Gordon within 3 months outperforms 15 times out of 27 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Carl L Gordon's insider trading performs compared to the benchmark.
Performance of Carl L Gordon
Average Return
13.42%
Outperforming Transactions
61%
1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
---|---|---|---|---|---|---|
Return(%) | 7.57 | 9.77 | 17.59 | 13.42 | -5.47 | -2.24 |
Relative Return to S&P 500(%) | 6.67 | 6.1 | 13.56 | 4.95 | -16.04 | -14.34 |
Carl L Gordon Ownership Network
Ownership Network List of Carl L Gordon
Ownership Network Relation of Carl L Gordon
Carl L Gordon Owned Company Details
What does Prevail Therapeutics Inc do?
Who are the key executives at Prevail Therapeutics Inc?
Carl L Gordon is the director & 10 percent owner of Prevail Therapeutics Inc. Other key executives at Prevail Therapeutics Inc include director & 10 percent owner Peter A. Thompson , General Counsel Kira M. Schwartz , and Chief Development Officer Franz Hefti .
Prevail Therapeutics Inc () Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Prevail Therapeutics Inc () in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Prevail Therapeutics Inc () were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Prevail Therapeutics Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.
Prevail Therapeutics Inc Insider Transactions
Carl L Gordon Mailing Address
Above is the net worth, insider trading, and ownership report for Carl L Gordon. You might contact Carl L Gordon via mailing address: 601 Lexington Avenue, 54th Floor, New York Ny 10022.